# US 2008/0306079 A1 · External preparation for allergic diseases

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0306079 A1
- Document ID: US20080306079A1
- Status: Published application
- Kind: A1
- Application number: 12/222,486
- Filed: 2008-08-11
- Published: 2008-12-11
- Earliest claimed: 2002-04-22
- Inventors: Akira Yagi; Takao Shida; Kokushin Ryu; Taiichi Kaku; Yoshiharu Kadota
- Web page: https://patentgrep.com/patent/US20080306079A1

## CPC

- A61K 31/4985: Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
- A61K 9/06: Ointments; Bases therefor; {Other semi-solid forms, e.g. creams, sticks, gels (composition of ointments, creams or gels A61K47/00)}
- A61P 17/00: Drugs for dermatological disorders
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- C07D 487/04: Ortho-condensed systems
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

The invention presents an external preparation for allergic diseases containing 3′-hydroxymethyl-4-hydroxypyrrolido [1,2-f]2′,5′-pipera-zinedione as an active ingredient. This compound has a prophylactic and therapeutic effect of allergic diseases, and the external preparation of the invention can be used in prophylaxis and treatment of various allergic diseases (for example, atopic dermatitis, urticaria, allergic rhinitis, allergic conjunctivitis, pollinosis, allergic asthma, and others).

## Claims

### Claim 1

A method for treating an allergic disease of type I comprising externally administering an effective amount of 3′-hydroxymethyl-4-hydroxypyrrolido [1,2-f] 2′, 5′-piperazinedione.

### Claim 2 (depends on 1)

The method of claim 1, wherein the allergic disease is atopic dermatitis, urticaria, allergic rhinitis, allergic conjunctivitis, pollinosis or allergic asthma.

### Claim 3 (depends on 2)

The method of claim 2, wherein the allergic disease is atopic dermatitis.

### Claim 4 (depends on 1)

The method of claim 1, wherein 3′-hydroxymethyl-4-hydroxypyrrolido[1,2-f]2′,5′-piperazinedione is formulated in an external preparation comprising ointment, liquid, lotion, spray, inhalant, nasal drops, eye drops, and bath salts.

### Claim 5 (depends on 1)

The method of claim 1, wherein 3′-hydroxymethyl-4-hydroxypyrrolido[1,2-f]2′,5′-piperazinedione is administered in a dose of from 1 mg/kg to 100 mg/kg.

### Claim 6 (depends on 5)

The method of claim 5, wherein 3′-hydroxymethyl-4-hydroxypyrrolido[1,2-f]2′,5′-piperazinedione is administered in a dose of from 2.5 mg/kg to 50 mg/kg.
